Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 5, Issue 1, 2009, Pages 4-16

  Snyder, Raymond D ^a   Boyle, Frances M ^b   Chan, Arlene ^c   Craft, Paul S ^d   Boer, Richard D E ^e   Mainwaring, Paul N ^f   Mccarthy, Nicole J ^g   Wilcken, Nicholas R ^h  

^a ST VINCENT S HOSPITAL   (Australia)

^b Mater Hospital   (Australia)

^c Mount Hospital   (Australia)

^d CANBERRA HOSPITAL   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f MATER ADULT HOSPITAL   (Australia)

^g ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^h WESTMEAD HOSPITAL   (Australia)

Author keywords

Breast neoplasm; Epidermal growth factor receptor (EGFR); ErbB 2receptor (HER2); Lapatinib; Medication therapy management

Indexed keywords

ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CARBAMAZEPINE; CLARITHROMYCIN; CORTISONE; CYTOCHROME P450 3A4; DEXAMETHASONE; EFAVIRENZ; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FOSPHENYTOIN SODIUM; HYDROCORTISONE; IRINOTECAN; LAPATINIB; LOPERAMIDE; MEPREDNISONE; MODAFINIL; NEVIRAPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG;

ACNE VULGARIS; ACTINIC KERATOSIS; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE PAIN; BRAIN METASTASIS; BREAST CANCER; CANCER INHIBITION; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERBILIRUBINEMIA; INTERSTITIAL LUNG DISEASE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LUNG TOXICITY; METASTASIS; NAUSEA; NEPHROTOXICITY; PARONYCHIA; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SELECTION; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN TOXICITY; THORAX PAIN; XEROSIS;

EID: 61649091368     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2009.01194.x     Document Type: Review

References (61)

1. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
2. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23: 4265-74.
3. Slamon D, Eiermann W, Robert N et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat 2006; 100: (Suppl. 1): Abstract 52.
4. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
5. Nahta R, Yu D, Hung M-C, Hortobagyi GN, Esteva FJ. Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3: 269-80.
6. Nahta R, Esteva FJ HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8: 215-23.
7. Manoir JM, Francia G, Man S et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006; 12: 904-16.
8. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18: 977-84.
9. Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004; 23: 646-53.
10. Nahta R, Yuan LXH, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007; 6: 667-74.
11. Rusnak DW, Alligood KJ, Mullin RJ et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumor cell lines. Cell Prolif 2007; 40: 580-94.
12. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-39.
13. Rodriguez AA, Chang J, Li X et al. Decrease in tumorigenic breast cancer cells with neoadjuvant lapatinib. Eur J Cancer Suppl 2008; 6: 108 (Abstract 204).
14. Gomez HL, Chavez MA, Doval DC et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. J Clin Oncol 2005; 23 (Suppl. 16): 203s (Abstract 3046).
15. Burstein HJ, Storniolo AM, Franco S et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008; 19: 1068-74.
16. Schwartz G, Chu QS-C, Hammond LA et al. Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. J Clin Oncol 2004; 22 (Suppl. 14): 212s (Abstract 3070).
17. Burris HA III, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23: 5305-13.
18. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43.
19. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-43 [Epub ahead of print].
20. Office of Oncology Drug Products. FDA Approves Tykerb (Lapatinib Tablets) for Advanced Metastatic Breast Cancer Patients. US Food and Drug Administration Center for Drug Evaluation and Research, Washington DC 2007. [Updated 16 March 2007; Cited 2 September 2008]. Available from: http://www.fda.gov/cder/offices/oodp/whatsnew/lapatinib.htm
21. Australian Drug Evaluation Committee. ADEC 252nd Meeting Recommendations, Resolution 9073. Australian Government Department of Health and Ageing, Therapeutic Goods Administration, Canberra 2007. [Updated 11 July 2007; Cited 2 September 2008]. Available from: http://www.tga.health.gov.au/docs/html/adec/adec0252.htm
22. Pharmaceutical Benefits Scheme. Pharmaceutical Benefits Schedule for Lapatinib. Australian Government Department of Health and Ageing, Canberra 2008. [Updated 1 September 2008; Cited 2 September 2008]. Available from: http://www.pbs.gov.au/html/healthpro/search/results?term= lapatinib&scope=PBS+STATIC&form-type=simple
23. European Medicines Agency. EPARs for Authorised Medicinal Products for Human Use: Tyverb (H-C-795). European Medicines Agency, London 2008. [updated 10 June 2008; cited 2 September 2008]. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/tyverb/tyverb.htm
24. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer v.2.2008. National Comprehensive Cancer Network, Fort Washington, PA 2008. [Cited 2 September 2008]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf
25. Toi M, Iwata H, Fujiwara Y et al. Biomarker analyses in Japanese refractory advanced breast cancer patients treated with lapatinib monotherapy. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, USA, 2007 (Abstract 5114).
26. Solomayer EF, Becker S, Pergola-Becker G et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 2006; 98: 179-84.
27. Fehm T, Becker S, Duerr-Stoerzer S et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 2007; 9: R74.
28. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 1-28.
29. Greshock J, Cheng J, Rusnak D et al. Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines. Mol Cancer Ther 2008; 7: 935-43.
30. Kirsch DG, Hochberg FH. Targeting HER2 in brain metastases from breast cancer. Clin Cancer Res 2003; 9: 5435-36.
31. Montagna E, Cancello G, D'Agostino D et al. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. Cancer Chemother Pharmacol 2008; 63: 275 [Epub ahead of print].
32. Gril B, Palmieri D, Bronder JL et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008; 100: 1092-103.
33. Boccardo F, Kaufman B, Baselga J et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU). J Clin Oncol 2008; 26 (Suppl. 15): 64s (Abstract 1094).
34. Lin NU, Paul D, Dieras V et al. Lapatinib and capecitabine for the treatment of brain metastases in patients with HER2+ breast cancer: An updated analysis from EGF105084. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, USA, 2007 (Abstract 6076).
35. Lin NU. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol 2007; 25 (Suppl. 18): 35s (Abstract 1012).
36. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26: 1993-99.
37. GlaxoSmithKline. Tykerb (lapatinib ditosylate) Australian Approved Product Information (Issue 2), 2007.
38. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83: 679-86.
39. Perez EA. Cardiac toxicity of ErbB2-targeted therapies: What do we know? Clin Breast Cancer 2008; 8: S114-20.
40. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332-44.
41. Winkeljohn DL. Oral chemotherapy medications: The need for a nurse's touch. Clin J Oncol Nurs 2007; 11: 793-96.
42. Kirk M, Hudis C. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 2008; 8: 155-61.
43. Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007; 12: 756-65.
44. MIMS. eMIMS DrugAlert (lapatinib). MIMS, Sydney 2008.
45. Koch KM, Beelen AP, Ho PTC, Roychowdhury DF. The value of label recommendations: How to dose lapatinib. J Clin Oncol 2007; 25: 5331-32.
46. Ratain MJ, Cohen EE. The value meal: How to save $1,700 per month or more on lapatinib. J Clin Oncol 2007; 25: 3397-98.
47. Messori A. Effect of food on lapatinib pharmacokinetics. J Clin Oncol 2007; 25: 5332-33.
48. Rahman A, Pazdur R, Wang Y, Huang S-M, Lesko L. The value meal: Effect of food on lapatinib bioavailability. J Clin Oncol 2007; 25: 5333-34.
49. Trippoli S. Controversies in using lapatinib at reduced dosage with food. J Clin Oncol 2007; 25: 5333.
50. Zhou X, Segreti A, Cameron D et al. Effect of lapatinib plus capecitabine (L+C) on quality of life (QOL) compared to capecitabine (C) alone in ErbB2+ metastatic breast cancer (MBC): An exploratory analysis. [ ]J Clin Oncol 2008; 26 (Suppl. 15): 509s (Abstract 9532).
51. Zhou X, Segreti A, Cella D et al. Lapatinib plus capecitabine versus capecitabine alone for ErbB2-positive metastatic breast cancer (MBC) - quality of life (QOL) assessment. Eur J Cancer Suppl 2008; 6: 216-17 (Abstract 565).
52. Sherrill B, Amonkar MM, Stein S, Walker M, Geyer C, Cameron D. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 2008; 99: 711-15.
53. Lin NU, Roché HH, Dieras V et al. A physician-reported neurological signs and symptoms worksheet (NSS WS) in EGF105084: A phase II study of lapatinib (lap) for pts with recurrent brain metastases (BM) from HER2+ breast cancer (BC). J Clin Oncol 2008; 26 (Suppl. 15): 60s (Abstract 1078)
54. Kaufman B, Weitzen R, Goldfarb A et al. A single-institution experience from the Lapatinib Expanded Access Program - effect of lapatinib and capecitabine combination therapy on CNS metastases in patients with ErbB2+ metastatic breast cancer. Eur J Cancer Suppl 2008; 6: 175 (Abstract 419).
55. De Placido S, Link J, Conte PF et al. Lapatinib Expanded Access Program (LEAP): Design, operation and initial safety data. Breast Cancer Research and Treatment, 2007: 106 (Suppl 1), (Abstract 6077).
56. Lacouture ME, Laabs SM, Koehler M et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008; [Epub ahead of print].
57. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 2006; 12: 131-41.
58. Crown JP, Burris HA, Boyle F et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008; 112: 317-25.
59. Benson AB III, Ajani JA, Catalano RB et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22: 2918-26.
60. Roche Products. Xeloda (capecitabine) Australian Approved Product Information, 2008.
61. Ewer MS, Perez EA, Baselga J et al. Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin®) in HER2-positive early breast cancer. Breast 2007; 16: S63 (Abstract P176).